N- (succinyl- beta- alanyl- L- leucyl- L- alanyl- L- leucyl)doxorubicin

09/01/2003 - "CPI-0004Na and sAIAL-Dox achieved statistically significant 70% tumor growth inhibition at day 22. "
04/15/2002 - "Dox levels in tumor tissue were 2-fold higher after treatment with CPI-0004Na than after treatment with an equimolar dose of Dox.HCl, whereas normal tissue levels were reduced 1.4-29-fold."
04/15/2002 - "Particularly, LS-174-T tumors that do not respond to Dox were inhibited by 68% after treatment with CPI-0004Na. "
04/15/2002 - "Tissue distribution studies performed with MCF-7/6 tumor-bearing nude mice and comparing CPI-0004Na and Dox.HCl confirmed that the improved activity of the prodrug is actually the result of selective generation and uptake of Dox at the tumor site. "
10/25/2001 - "N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity."

07/01/2004 - "Our results indicate that, Dox has no effect on the number of lung metastases while CPI-0004Na induces a 38.3% reduction on average. "
07/01/2004 - "When considering the effect on the proportion of the lungs' surface covered by metastases, Dox induces a 39% reduction while the prodrug CPI-0004Na is about two fold more active with a 71% decrease."
07/01/2004 - "CPI-0004Na, a new doxorubicin prodrug, reduces growth of 3LL-H61 carcinoma lung metastases in C57BI/6 mice."

07/01/2004 - "CPI-0004Na, a new doxorubicin prodrug, reduces growth of 3LL-H61 carcinoma lung metastases in C57BI/6 mice."